Marshak Richard 4

What Happened Richard Marshak, Chief Commercial Officer of TriSalus Life Sciences (TLSI), acquired 561 shares on June 30, 2026. The shares were issued at $3.87 each for a total value of $2,171. This transaction is reported as an acquisition/award (code A) and reflects participation in the issuer’s Employee Stock Purchase Plan rather than an open-market purchase.

Key Details

• Transaction date: 2026-06-30; Form 4 filed: 2026-07-01 (timely within the usual two-business-day window).
• Shares acquired: 561 at $3.87 per share; aggregate value $2,171.
• Shares owned after transaction: not specified in the available filing.
• Footnote: F1 — shares acquired through the Issuer's Employee Stock Purchase Plan in a transaction exempt under Rule 16b-3.
• Filing timeliness: No late filing flag reported.

Context This was an acquisition via the company’s Employee Stock Purchase Plan (ESPP). Transactions under an ESPP are common ways for employees to accumulate company stock and are generally exempt from short-swing profit rules under Rule 16b-3. Purchases by officers can be of interest to investors, but this small ESPP purchase should be viewed as routine compensation/benefit participation rather than a standalone market signal.